We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Discovery and Manufacturing Strategies for Novel, Homogeneous ADC Molecules

Video   Dec 23, 2016

 

Several key learnings have emerged through application of rapid re-iterative ADC design using reactive non-natural amino acids to specifically position conjugation sites: Site-specific homogeneous molecules can improve therapeutic index preclinically and have the potential to optimize clinical impact for a given combination of antibody and warhead. Site matters. Homogeneity is required, but not sufficient, for best in class molecules. Finding the optimal site for conjugation is crucial. Beyond antibody stability, PK and attributes that optimize for internalization and cell killing in vitro, certain conjugation sites on the antibody further enhance solid tumor killing efficacy in vivo. The antibody production process has been split into two stages; First the production of the ribosome-rich extract that can now be considered a critical raw material. And secondly, use of that cell-free extract to produce nnAA containing antibodies in 10 hours from DNA. Each stage has been optimized for speed, efficiency and flexibility and now established as a viable manufacturing process: Removal of RF-1 from the extract permits very efficient production of nnAA containing Use of novel nnAAs allows complete conjugation in minutes Extracts that incorporate orthogonal tRNAs and lack RF-1 provide for efficient and flexible manufacturing.

 
 
 
 

Recommended Videos

A "Living Drug" That Could Change the Way We Treat Cancer

Video

In a talk about a breakthrough, CAR T-cell therapy pioneer, Carl June shares how three decades of research culminated in a therapy that's eradicated cases of leukemia once thought to be incurable – and explains how it could be used to fight other types of cancer.

WATCH NOW

CAR T-cell Therapy: Reprogramming the Immune System To Treat Cancer

Video

Researchers are developing third generation CAR-T immunotherapy treatments which aim to be more effective with less side effects than previous therapies.

WATCH NOW

ADDomer – A New Kind of Vaccine for Untreatable Infection

Video

Scientists from the University of Bristol, CNRS and Imophoron Ltd worked with the computer technology giant Oracle to develop a new kind of vaccine that needs no refrigeration. They used synthetic biology, cryo-electron microscopy and high-performance cloud computing to produce a candidate vaccine against the mosquito-borne chikungunya virus. Their findings could revolutionise the way vaccines are designed, developed and stored.

WATCH NOW

 

Like what you just watched? You can find similar content on the communities below.

Biopharma Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE